Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

VRCA

Verrica Pharmaceuticals Inc

Jan 30 • 04:00PM ET

0.7172

Dollar change -0.0019
Percentage change -0.26	%

Healthcare • Biotechnology • USA • NASD

Peers: DERM HRTX ACRS SUPN CLSD KPTI XERS ADMA DMAC EYPT

| Held by: VTI IWM VXF IWO VTWO IWC QQQS VTWG RSSL UWM

Index	RUT	P/E	-	EPS (ttm)	-1.83	Insider Own	45.86%	Shs Outstand	90.56M	Perf Week	-1.75%
Market Cap	64.96M	Forward P/E	-	EPS next Y	-0.60	Insider Trans	-0.35%	Shs Float	49.03M	Perf Month	4.81%
Income	-84.99M	PEG	-	EPS next Q	-0.25	Inst Own	15.84%	Short Float	3.72%	Perf Quarter	-54.03%
Sales	9.21M	P/S	7.05	EPS this Y	2.30%	Inst Trans	-34.44%	Short Ratio	2.56	Perf Half Y	-89.28%
Book/sh	-0.75	P/B	-	EPS next Y	58.51%	ROA	-130.68%	Short Interest	1.82M	Perf Year	-88.03%
Cash/sh	0.25	P/C	2.83	EPS next 5Y	-	ROE	-2059.89%	52W Range	0.61 - 11.41	Perf YTD	2.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-0.97%	ROI	-714.15%	52W High	-93.71%	Beta	1.49
Dividend TTM	-	Quick Ratio	1.22	Sales past 5Y	-17.00%	Gross Margin	72.90%	52W Low	17.40%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	1.34	EPS Y/Y TTM	-69.90%	Oper. Margin	-812.68%	RSI (14)	46.72	Volatility	7.01% 8.91%
Employees	100	Debt/Eq	-	Sales Y/Y TTM	187.45%	Profit Margin	-922.81%	Recom	2.20	Target Price	3.33
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	9.27%	Payout	-	Rel Volume	0.14	Prev Close	0.72
Sales Surprise	-133.85%	EPS Surprise	-30.22%	Sales Q/Q	-161.06%	Earnings	Nov 04 AMC	Avg Volume	712.27K	Price	0.72
SMA20	3.07%	SMA50	-12.23%	SMA200	-81.83%	Trades		Volume	98,354	Change	-0.26%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-06-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-25-23	Upgrade	Needham	Hold → Buy	$10
Mar-22-23	Initiated	Jefferies	Buy	$10
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$4 → $11
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16 → $4
May-14-21	Initiated	RBC Capital Mkts	Outperform	$19
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$18 → $21
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy	$24 → $18
Jun-24-20	Initiated	Northland Capital	Outperform	$21
Mar-24-20	Initiated	Needham	Buy	$20
Feb-21-19	Initiated	H.C. Wainwright	Buy	$20

Show Previous Ratings

Jan-21-25 07:00AM	Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference (GlobeNewswire) +5.12%
Dec-20-24 07:00AM	Verrica Provides Business and Operational Update (GlobeNewswire)
Dec-09-24 04:15PM	Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.94% -7.84%
Dec-06-24 08:00AM	Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan (GlobeNewswire)
Nov-21-24 07:30AM	Verrica Announces Pricing of $42.0 Million Public Offering (GlobeNewswire) +11.56%
04:05PM	Loading…
Nov-20-24 04:05PM	Verrica Announces Proposed Public Offering (GlobeNewswire)
Nov-04-24 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition (GlobeNewswire) -6.54% -44.23%
Oct-24-24 07:00AM	Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-09-24 06:21PM	Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... (GuruFocus.com)
Oct-02-24 07:30AM	Verrica Pharmaceuticals Announces Restructuring of Commercial Organization (GlobeNewswire) -18.98%
Sep-29-24 08:02AM	Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:27AM	Is Verrica Pharmaceuticals Inc. (VRCA) The Worst 52-Week Low Stocks to Buy Now According to Short Sellers? (Insider Monkey) -5.68%
Sep-20-24 05:21AM	Notice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA) (Newsfile) -6.70%
Sep-04-24 07:30AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York (GlobeNewswire) +5.50%
Aug-15-24 07:32AM	Verrica stock drops after half patients tumours gone in skin cancer trial (Clinical Trials Arena) -6.73%
09:52AM	Loading…
Aug-14-24 09:52AM	Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday? (Benzinga) -40.80%
08:55AM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:45AM	Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results (GlobeNewswire)
07:30AM	Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma (GlobeNewswire)
Aug-06-24 07:30AM	Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 (GlobeNewswire) -5.45%
Jul-15-24 11:57AM	7 Short-Squeeze Stocks That Could Beat Down the Bears (InvestorPlace)
Jul-01-24 07:30AM	Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. (GlobeNewswire) +9.05%
May-30-24 04:30PM	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York (GlobeNewswire)
May-15-24 09:11AM	Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth (MT Newswires)
07:30AM	Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts (GlobeNewswire)
May-14-24 09:28AM	HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $14 From $13, Maintains Buy Rating (MT Newswires)
08:50AM	Needham Adjusts Price Target on Verrica Pharmaceuticals to $16 From $8, Keeps Buy Rating (MT Newswires)
03:01AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 11:53AM	VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +19.50%
09:12AM	Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review (GuruFocus.com)
08:40AM	Loading…
08:40AM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 07:30AM	Verrica Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-08-24 07:30AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
May-06-24 06:35AM	Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last? (Zacks)
Apr-27-24 06:00AM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-02-24 07:30AM	Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 07:30AM	Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA (GlobeNewswire) +5.14%
Mar-01-24 09:10AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.31%
Feb-29-24 08:11AM	Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results (GuruFocus.com) -7.87%
07:30AM	Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 07:30AM	Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire)
Feb-22-24 07:30AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 (GlobeNewswire)
Feb-05-24 07:30AM	Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition (GlobeNewswire) -7.58%
Jan-29-24 07:30AM	Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH from Centers for Medicare and Medicaid Services (GlobeNewswire)
Jan-22-24 07:44PM	7 Potential Short-Squeeze Stocks Poised for Rapid Gains (InvestorPlace)
Jan-05-24 07:30AM	Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma (GlobeNewswire)
Jan-04-24 07:30AM	Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH for the Treatment of Common Warts (GlobeNewswire)
Jan-03-24 07:30AM	Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH (GlobeNewswire)
Dec-15-23 01:49PM	Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today? (InvestorPlace) +61.97%
06:00AM	Verrica Pharmaceuticals' Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan (GlobeNewswire)
Nov-11-23 10:13AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 08:00AM	Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-09-23 07:30AM	Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results (GlobeNewswire) -9.83%
Oct-25-23 07:00AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023 (GlobeNewswire)
Sep-27-23 08:00AM	Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023 (GlobeNewswire)
Aug-31-23 08:00AM	Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-24-23 08:30AM	Verrica Pharmaceuticals Announces First Sale of YCANTH to FFF Enterprises (GlobeNewswire)
Aug-23-23 07:30AM	Verrica Issues Statement in Support of FDAs Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum (GlobeNewswire)
Aug-10-23 04:05PM	Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting (GlobeNewswire)
Aug-08-23 07:30AM	Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 07:30AM	Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Associations (AAD) 2023 Innovation Academy Meeting (GlobeNewswire)
Jul-27-23 06:06AM	Verrica Pharmaceuticals Chairman of the Board Acquires 1.3% More Stock (Simply Wall St.)
Jul-26-23 04:05PM	Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed (GlobeNewswire)
Jul-25-23 07:16AM	Daily Vickers Top Buyers & Sellers for 07/25/2023 (Argus Research)
Jul-24-23 03:16PM	Why Shares of Verrica Pharmaceuticals Are Plummeting on Monday (Motley Fool) -31.46%
07:00AM	Following FDA Approval of YCANTH for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET (GlobeNewswire)
Jul-21-23 04:47PM	UPDATE 2-Verrica's drug gets US nod as first treatment for a type of skin infection (Reuters)
04:30PM	US FDA approves Verrica's skin disease treatment (Reuters)
04:24PM	Verrica Pharmaceuticals Announces FDA Approval of YCANTH (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum (GlobeNewswire)
Jul-17-23 07:22AM	With a 39% stake, Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders have a lot riding on the company (Simply Wall St.) +6.43%
Jul-12-23 03:16AM	Net Asset Value(s) (Business Wire)
May-31-23 07:00AM	Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York (GlobeNewswire) +6.58%
May-30-23 12:34PM	We're Not Worried About Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn (Simply Wall St.) -7.48%
May-10-23 07:30AM	Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
06:11AM	Verrica Pharmaceuticals First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
May-09-23 07:30AM	Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-05-23 09:07AM	The past three years for Verrica Pharmaceuticals (NASDAQ:VRCA) investors has not been profitable (Simply Wall St.)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-12-23 07:00AM	Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma (GlobeNewswire)
Apr-11-23 07:00AM	Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-06-23 07:30AM	Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results (GlobeNewswire)
Feb-28-23 04:05PM	Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-27-23 04:05PM	Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum (GlobeNewswire) -5.47%
Feb-22-23 11:49AM	Verrica Pharmaceuticals expects $32.5M from the sale of stock and warrants (American City Business Journals)
Feb-21-23 07:22AM	Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +5.56%
Feb-17-23 06:43PM	12 Most Promising Micro-Cap Stocks According to Analysts (Insider Monkey) +8.34%
Feb-14-23 10:15AM	2 Breakout Growth Stocks to Buy for the Long Haul (Motley Fool)
Jan-24-23 07:30AM	Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum (GlobeNewswire)
07:16AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders have significant skin in the game with 40% ownership (Simply Wall St.)
Jan-04-23 07:30AM	Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions (GlobeNewswire) +14.93%
Jan-01-23 08:16AM	Bullish insiders bet US$11m on Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) (Simply Wall St.)
Dec-12-22 12:07PM	We're Not Very Worried About Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Rate (Simply Wall St.)
Nov-26-22 07:00AM	Investors in Verrica Pharmaceuticals (NASDAQ:VRCA) have unfortunately lost 83% over the last three years (Simply Wall St.)
Nov-07-22 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results (GlobeNewswire) -6.72%
Aug-31-22 04:30PM	Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +8.89%
Aug-17-22 07:53AM	Is Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Popular Amongst Insiders? (Simply Wall St.)
Aug-11-22 07:30AM	Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results (GlobeNewswire) +5.22%
Aug-04-22 01:38PM	Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up (Zacks)
12:34PM	Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y (Zacks)

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hayes Christopher G.	CHIEF LEGAL OFFICER	Aug 26 '24	Sale	2.66	26,183	69,647	115,303	Aug 28 04:15 PM
Hayes Christopher G.	CHIEF LEGAL OFFICER	Aug 27 '24	Sale	2.46	9,530	23,444	105,773	Aug 28 04:15 PM
Goldenberg Gary	Chief Medical Officer	Aug 26 '24	Sale	2.66	9,888	26,302	97,862	Aug 28 04:15 PM
Goldenberg Gary	Chief Medical Officer	Aug 27 '24	Sale	2.46	3,601	8,858	94,261	Aug 28 04:15 PM
Bonaccorso Joe	CHIEF COMMERCIAL OFFICER	Aug 26 '24	Sale	2.66	24,709	65,726	82,107	Aug 28 04:15 PM
Bonaccorso Joe	CHIEF COMMERCIAL OFFICER	Aug 27 '24	Sale	2.46	8,993	22,123	73,114	Aug 28 04:15 PM
Kohler Terry	CHIEF FINANCIAL OFFICER	Aug 26 '24	Sale	2.66	21,820	58,041	52,596	Aug 28 04:15 PM
Kohler Terry	CHIEF FINANCIAL OFFICER	Aug 27 '24	Sale	2.46	7,899	19,432	44,697	Aug 28 04:15 PM
White Ted	PRESIDENT AND CEO	Aug 26 '24	Sale	2.66	24,979	66,444	224,988	Aug 28 04:15 PM
White Ted	PRESIDENT AND CEO	Aug 27 '24	Sale	2.46	9,021	22,192	215,967	Aug 28 04:15 PM
Hayes Christopher G.	Officer	Aug 26 '24	Proposed Sale	2.62	36,000	94,300		Aug 26 04:45 PM
Goldenberg Gary	Officer	Aug 26 '24	Proposed Sale	2.64	14,000	37,000		Aug 26 04:35 PM
White Ted	Officer	Aug 26 '24	Proposed Sale	2.65	34,000	90,100		Aug 26 03:31 PM
Bonaccorso Joe	Officer	Aug 26 '24	Proposed Sale	2.65	34,000	90,100		Aug 26 03:17 PM
Kohler Terry	Officer	Aug 26 '24	Proposed Sale	2.65	30,000	79,500		Aug 26 03:08 PM
White Ted	PRESIDENT AND CEO	Jul 22 '24	Sale	7.06	32,469	229,231	250,121	Jul 23 06:13 PM
White Ted	PRESIDENT AND CEO	Jul 23 '24	Sale	6.98	154	1,075	249,967	Jul 23 06:13 PM
Bonaccorso Joe	CHIEF COMMERCIAL OFFICER	Jul 22 '24	Sale	7.06	25,461	179,755	106,931	Jul 23 06:12 PM
Bonaccorso Joe	CHIEF COMMERCIAL OFFICER	Jul 23 '24	Sale	6.98	115	803	106,816	Jul 23 06:12 PM
Goldenberg Gary	Chief Medical Officer	Jul 22 '24	Sale	7.06	18,421	130,052	107,836	Jul 23 06:11 PM
Goldenberg Gary	Chief Medical Officer	Jul 23 '24	Sale	6.98	86	600	107,750	Jul 23 06:11 PM
Hayes Christopher G.	CHIEF LEGAL OFFICER	Jul 22 '24	Sale	7.06	21,649	152,842	141,577	Jul 23 06:10 PM
Hayes Christopher G.	CHIEF LEGAL OFFICER	Jul 23 '24	Sale	6.98	91	635	141,486	Jul 23 06:10 PM

Dollar change -0.02
Percentage change -1.33	%

TSHA Taysha Gene Therapies Inc daily Stock Chart

Peers: SRPT CRSP NTLA BLUE QURE EDIT IOVA ADVM SGMO GNFT

| Held by: VTI IWM XBI VXF IWO IBB VTWO IWC LABU VTWG

Index	RUT	P/E	-	EPS (ttm)	-0.03	Insider Own	25.05%	Shs Outstand	204.94M	Perf Week	-3.27%
Market Cap	303.31M	Forward P/E	-	EPS next Y	-0.38	Insider Trans	0.00%	Shs Float	153.61M	Perf Month	-15.43%
Income	-22.77M	PEG	-	EPS next Q	-0.08	Inst Own	69.38%	Short Float	15.59%	Perf Quarter	-24.87%
Sales	9.91M	P/S	30.61	EPS this Y	61.44%	Inst Trans	-0.77%	Short Ratio	5.18	Perf Half Y	-34.22%
Book/sh	0.43	P/B	3.42	EPS next Y	-1.39%	ROA	-12.11%	Short Interest	23.95M	Perf Year	-7.50%
Cash/sh	0.77	P/C	1.92	EPS next 5Y	-	ROE	-114.77%	52W Range	1.19 - 4.32	Perf YTD	-14.45%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-137.69%	ROI	-15.23%	52W High	-65.74%	Beta	0.90
Dividend TTM	-	Quick Ratio	5.51	Sales past 5Y	129.39%	Gross Margin	86.98%	52W Low	24.37%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	5.51	EPS Y/Y TTM	98.69%	Oper. Margin	-831.93%	RSI (14)	32.35	Volatility	5.52% 7.74%
Employees	52	Debt/Eq	0.70	Sales Y/Y TTM	-30.90%	Profit Margin	-229.67%	Recom	1.09	Target Price	6.59
Option/Short	Yes / Yes	LT Debt/Eq	0.68	EPS Q/Q	89.77%	Payout	-	Rel Volume	0.23	Prev Close	1.50
Sales Surprise	2.79%	EPS Surprise	-15.34%	Sales Q/Q	-62.33%	Earnings	Nov 13 AMC	Avg Volume	4.62M	Price	1.48
SMA20	-11.03%	SMA50	-27.36%	SMA200	-35.58%	Trades		Volume	1,071,303	Change	-1.33%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$5
Apr-09-24	Initiated	Piper Sandler	Overweight	$9
Feb-01-23	Downgrade	Jefferies	Buy → Hold	$14 → $1.50
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$23 → $3
Nov-09-22	Downgrade	Goldman	Buy → Neutral	$16 → $3
Mar-09-22	Initiated	Robert W. Baird	Outperform	$26
Mar-01-22	Initiated	Wells Fargo	Overweight	$25
Feb-18-22	Initiated	SMBC Nikko	Outperform	$25
Dec-16-21	Initiated	Guggenheim	Buy	$28
Jul-16-21	Initiated	Needham	Buy	$45
Jun-24-21	Initiated	Truist	Buy	$60
Jun-15-21	Initiated	BTIG Research	Buy	$44
Jun-09-21	Initiated	Wedbush	Outperform	$31
Jun-08-21	Initiated	JMP Securities	Mkt Outperform	$40
May-19-21	Initiated	Cantor Fitzgerald	Overweight	$44
May-11-21	Resumed	Jefferies	Buy	$34 → $45
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform	$42
Oct-19-20	Initiated	Morgan Stanley	Overweight	$29
Oct-19-20	Initiated	Jefferies	Buy	$34

Show Previous Ratings

Jan-03-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-06-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-24 12:51PM	Q3 2024 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
02:16AM	Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ... (GuruFocus.com)
Nov-13-24 05:15PM	Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.53%
04:01PM	Loading…
04:01PM	Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-24 08:00AM	Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13 (GlobeNewswire) +7.87%
Nov-01-24 04:30PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.47% -12.42%
Oct-22-24 08:00AM	Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress (GlobeNewswire)
Oct-16-24 03:42PM	Is Taysha Gene Therapies, Inc. (TSHA) the Most Promising Biotech Stock According to Hedge Funds? (Insider Monkey)
Oct-14-24 12:00PM	Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why (Zacks)
Oct-04-24 08:01AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-03-24 04:55AM	Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5? (Insider Monkey)
Sep-26-24 08:00AM	Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress (GlobeNewswire)
Sep-06-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:10AM	Loading…
Aug-12-24 09:10AM	Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:01AM	Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-24 08:00AM	Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12 (GlobeNewswire)
Aug-02-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-05-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-26-24 09:14AM	Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -17.24%
08:36AM	Why Is Taysha Gene Therapies (TSHA) Stock Down 14% Today? (InvestorPlace)
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-25-24 06:34PM	Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -7.33%
Jun-18-24 07:30AM	Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome (GlobeNewswire) -26.30%
07:02AM	Sanofi taps Belharra for immune drug research; AstraZenecas new cancer drug falls short (BioPharma Dive)
Jun-13-24 06:00AM	How to Invest in Penny Stocks in 2024: 3 Best Picks (InvestorPlace) +6.65%
Jun-12-24 07:00AM	Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting (GlobeNewswire)
Jun-07-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-24 04:31PM	Is Taysha Gene Therapies, Inc. (NASDAQ:TSHA) the Best Gene Therapy Company? (Insider Monkey) +5.54%
04:17PM	Loading…
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
May-15-24 03:11AM	Taysha Gene Therapies Inc (TSHA) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com) +21.01%
May-14-24 08:57PM	TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +7.08%
05:15PM	Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:03PM	Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours (MT Newswires)
04:01PM	Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-24 04:05PM	Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14 (GlobeNewswire) -5.34%
May-03-24 04:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 10:01AM	Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know (Zacks) +6.61%
08:00AM	Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome (GlobeNewswire)
Apr-29-24 01:37PM	These 2 Strong Buy Penny Stocks Could Rally to $9, Says Piper Sandler (TipRanks)
Apr-15-24 05:30AM	Certain Biotech Investors Get an Early Look at Results. Is That Fair? (The Wall Street Journal) -9.52%
Apr-05-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-20-24 11:19AM	Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2023 Earnings Call Transcript (Insider Monkey) +31.56%
08:01AM	Q4 2023 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-24 08:53PM	TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +5.63%
04:01PM	Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates (GlobeNewswire)
Mar-14-24 04:26PM	Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19 (GlobeNewswire) -5.31% +7.48%
Mar-01-24 05:08PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.12%
Feb-29-24 08:00AM	Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome (GlobeNewswire) +19.70%
Feb-15-24 04:01PM	Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs (GlobeNewswire) +8.90% +20.13%
Feb-02-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-31-24 02:23PM	7 Micro-Cap Stocks That Could Majorly Surprise Investors (InvestorPlace)
Jan-22-24 08:00AM	Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference (GlobeNewswire)
Jan-15-24 09:30AM	3 Growth Stocks That Could Go Parabolic in 2024 (Motley Fool)
Jan-10-24 08:00AM	Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome (GlobeNewswire) -7.29%
Jan-05-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-19-23 07:30AM	Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies (PR Newswire)
Nov-29-23 08:00AM	Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients (GlobeNewswire)
Nov-15-23 02:00PM	Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2023 Earnings Call Transcript (Insider Monkey) +26.32%
12:52PM	Q3 2023 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 06:35PM	Taysha Gene Therapies Inc (TSHA) Reports Q3 2023 Financial Results and Clinical Progress (GuruFocus.com)
04:08PM	Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates (GlobeNewswire)
Nov-07-23 08:00AM	Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14 (GlobeNewswire)
Oct-24-23 08:00AM	Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress (GlobeNewswire)
Oct-10-23 08:00AM	Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress (GlobeNewswire) -5.97%
Sep-26-23 08:00AM	Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome (GlobeNewswire)
Sep-19-23 04:01PM	Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN) (GlobeNewswire) +5.16% -6.13%
Sep-05-23 09:55AM	Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Sep-04-23 03:04PM	3 Small-Cap Stocks to Sell in September Before They Crash & Burn (InvestorPlace)
Aug-24-23 08:00AM	Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome (GlobeNewswire) +5.41%
Aug-15-23 01:54AM	Q2 2023 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 07:02AM	Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results (GlobeNewswire) +188.23%
07:00AM	Taysha Gene Therapies Announces $150 Million Private Placement Financing (GlobeNewswire)
Jul-31-23 08:00AM	Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome (GlobeNewswire)
Jul-18-23 07:08AM	Taysha Gene Therapies Insiders Added US$3.0m Of Stock To Their Holdings (Simply Wall St.)
Jun-28-23 08:00AM	Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day (GlobeNewswire)
Jun-15-23 08:00AM	Taysha Gene Therapies to Host Virtual R&D Day on Lead Clinical Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome (GlobeNewswire)
Jun-05-23 08:00AM	Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome (GlobeNewswire) +5.06%
May-19-23 12:54PM	Taysha Gene Therapies Touts Encouraging Preclinical Data From Rett Syndrome Candidate (Benzinga) +5.64%
08:00AM	Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire)
May-16-23 11:41AM	Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 10:15AM	Q1 2023 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents) -5.30%
May-11-23 04:01PM	Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.47%
May-04-23 08:00AM	Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11 (GlobeNewswire) +5.20%
Apr-27-23 04:52PM	Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire) +16.10%
Apr-15-23 08:24AM	Even after rising 30% this past week, Taysha Gene Therapies (NASDAQ:TSHA) shareholders are still down 84% over the past year (Simply Wall St.)
Mar-30-23 06:08AM	Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2022 Earnings Call Transcript (Insider Monkey) +11.37%
Mar-28-23 04:01PM	Taysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -6.19%
Mar-15-23 04:01PM	Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28 (GlobeNewswire) -10.17%
Feb-14-23 05:32PM	How patients' families pushed rare-disease therapy to cusp of clinical trial until biotech's cash halted progress (American City Business Journals)
Feb-08-23 05:42AM	A Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider increased their holdings by 28% last year (Simply Wall St.)
Jan-31-23 04:01PM	Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook (GlobeNewswire) +6.49% -26.22%
Jan-24-23 02:32PM	Biotech signals potential pullback from 200-job Durham plant (American City Business Journals)
Dec-19-22 02:05PM	Dallas-based Taysha Gene Therapies names board chair as new CEO (American City Business Journals) -9.35%
Dec-16-22 06:19PM	Taysha Gene Therapies Announces Executive Leadership Changes (GlobeNewswire) -6.96%
Dec-01-22 09:55AM	Taysha Gene Therapies, Inc. (TSHA) Could Find Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-29-22 04:01PM	Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-08-22 07:00AM	Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +10.00%
Nov-03-22 08:26PM	These 2 Stocks May Be Reaching a Bottom; Insiders Are Buying the Dip (TipRanks) +11.43%

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Manning Paul B	10% Owner	Jun 27 '24	Buy	2.25	1,333,333	2,999,999	1,333,333	Jul 01 08:00 AM

VRCA

Verrica Pharmaceuticals Inc

TSHA

Taysha Gene Therapies Inc

Upgrade your FINVIZ experience